RespireRx Pharmaceuticals Inc. — Cyborg Score 3/10
Challenged
Neurological drug development
Strategic Profile
The company has moved its core drug platforms into separate subsidiaries: ResolutionRx Ltd (cannabinoids) and EndeavourRx LLC (neuromodulators). The company's lead GABAkine, KRM-II-81, is in preclinical development for the treatment of epilepsy, with funding from the National Institutes of Health. RespireRx has stated it plans to file a Form 10 to return to public status, with indication it would wait until after December 31, 2025, to file this form.
Cyborg Score Rationale
The company faces significant structural challenges following its SEC registration revocation in November 2025, with extremely low market capitalization (~$650K-$850K as of March 2026) and minimal public trading activity. However, it maintains a 39-year operating history, holds promising neurological drug candidates, and has secured NIH funding for preclinical development.
Top Insights
SEC registration revoked (November 14, 2025) but shares remain valid unregistered securities; company plans Form 10 filing to restore public status
Lead candidate KRM-II-81 (GABAkine for epilepsy) received $1.5M NIH grant for preclinical toxicology work (September 2025–August 2026)
Corporate restructuring moved cannabinoid platform to ResolutionRx Ltd subsidiary and neuromodulator platform to EndeavourRx LLC subsidiary
$45 million private placement announced to raise capital, creating significant shareholder dilution risk for existing holders
Named Competitors
Vyvanse/Adhansia — ADHD and psychiatric disorder treatments
Seizure Management Portfolio — Anti-epileptic drugs and neurological therapies
Sleep and Neurological Disorder Treatments — Neuropsychiatric and neurological drug development
Recent Developments
(November 2025) SEC revoked public registration of securities; company announced plans to refile as Form 10
(September 2025) Received $1.5M NIH grant for KRM-II-81 preclinical development (2-year period through August 2027)
(March 2026) Shares trading OTC at $0.0018 with market cap ~$658K; company announced $45M private placement offering
Open the full interactive RespireRx Pharmaceuticals Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.